New Full-Cycle Manufacturing Facility for Innovative Pharmaceutical Ingredients Is Being Built in Khimki

ChemRar Group, the domestic market leader in the development and manufacture of innovative pharmaceuticals, is expanding its manufacturing capacity by building a new high-tech complex that will include the manufacture of active pharmaceutical ingredients, storage facilities and a workshop for the development of intermediates for APIs. 

API-Technologies’ new production line will increase the company’s capacity by more than five times. Total investment in the project will exceed 1 billion rubles.

API-Technologies project is supported by the Industry Development Fund under the Ministry of Industry and Trade of the Russian Federation, as well as the Government of the Moscow Region. The facility construction permit was issued by Glavgosstroynadzor of the Moscow Region.

The Production complex will be located on the territory of the ChemRar High-Tech Centre in Khimki, Moscow Region, where a full cycle of research, development and manufacture of both import-substituting and innovative medicines of the new generation for the treatment of diseases of the central nervous system, oncology, HIV infection, as well as influenza, coronavirus, etc. is already in progress.

It is planned that the new manufacturing site will manufacture ingredients for innovative drugs from the company’s current product portfolio, such as ELPIDA® against HIV infection and AVIANDR® for the treatment of anxiety disorders, including those arising after coronavirus infection.

Establishment of the company’s own technological line for the manufacture of intermediates and active pharmaceutical ingredients on the territory of Russia is of great strategic importance for ensuring the country’s drug security, especially against the background of logistical problems and difficulties with the supply of substances required for the manufacture of drugs from abroad.

The construction is planned to be fully completed by the end of 2024, and the full launch of manufacture will take place in the I-II quarter of 2025. The manufacture launching will also create up to 50 new jobs. 

“Russian innovations need Russian full-cycle manufacture. In recent years, all pharmaceutical manufacturers have often faced interruptions or no possibility at all to have ingredients and reagents to be supplied for them from abroad, which led to either a shortage of some drugs in the market, or to a significant increase in the cost of drug manufacture, when it was necessary to develop the ingredients “from the ground”, conducting 10-15 stages of intermediates synthesis. But in emergency situations, such as the COVID-19 pandemic, it was justified. But now, it is obvious to everyone that all stages of drug development in full should be localized in Russia”, – commented Sergey Ashotovich Restevanyan, Director General of API-Technologies, LLC on the new manufacturing facility construction.

ChemRar Group of Companies unites research and manufacturing organizations in the field of development of innovative drugs, diagnostics, prophylaxis and new methods of life-threatening diseases treatment in Russia and abroad. ChemRar Group has all the necessary competencies and a unique integrated technological platform for the development of innovative and modern high quality generic drugs on a full cycle basis, starting from the early stages of molecule search, preclinical and clinical trials to registration and launch of the drug onto the market.